Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report)’s stock price traded down 4% during trading on Thursday after ...
The Company is currently analyzing the case and will update the prescribing information for Elevidys to note this development.
Influenza vaccine recommendations made for upcoming season; patient dies following Elevidys infusion; Chikungunya vaccine now available and recommended ...
Stocktwits on MSN1d
Sarepta Therapeutics Stock Has A Nightmarish Week After DMD Patient Death, But Retail And Analysts Aren't Giving UpShares of Sarepta Therapeutics Inc. have lost more than 26% this week, heading for their worst such performance in over a ...
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its price target reduced by stock analysts at Deutsche Bank ...
AstraZeneca signed a deal with Alteogen worth up to $1.35 billion for subcutaneous cancer drugs. Taiho Pharmacetical bought ...
Sarepta stock may recover sharply as additional information and data reveal that the adverse event reported by the company is ...
After Sarepta reported the death of a patient who had recently taken the gene therapy Elevidys, patient advocacy group Parent ...
Scotiabank lowered the firm’s price target on Sarepta (SRPT) to $80 from $105 and keeps a Sector Perform rating on the shares. After speaking ...
The firm's stock price dropped 27 percent on Tuesday following the news that the young man died from acute liver failure after getting Elevidys.
Cambridge, Mass.-based Sarepta Therapeutics reported the first known death from its Duchenne muscular dystrophy gene therapy ...
A patient died from liver injury while taking the gene therapy Elevidys Sarepta says more than 800 patients have received the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback